This article provides an overview of solutions to address key challenges facing vaccine developers or CDMOs wishing to build their own commercial-scale mRNA production facilities.
Oliver Excell
Advertisement
Oliver Excell is an implementation expert at PA Consulting.
Articles by Oliver Excell
Advertisement
Latest Updated Articles
Overcoming Engineering Challenges to Enable Commercial Scale mRNA Vaccine ManufacturingPublished: August 2nd 2022 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
New Cellevate Nanofiber Microcarriers Aim to Transform Vaccine Manufacturing Processes
2
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
3
Everything to Know About Cell and Gene Therapy in 2025
4
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
5
